secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-131746
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026
--------------------------------------------------------------------------------

- Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.
- Cash, equivalents and short-term investments $238.3M at Dec 31, 2025; funds operations into H2 2027.
- R&D expenses $184.7M for FY2025, up from $119.4M due to Phase 3 ARCHER II and regulatory filings.
- Vonaprument Phase 3 ARCHER II topline data in geographic atrophy expected Q4 2026; enrollment completed July 2025.
- Tanruprubart MAA filed in EU for GBS; U.S. BLA submission planned in 2026 based on FORWARD study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/0001193125-26-131746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/annx-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-131746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer